How should a physician discuss treatment risks with the father of a pediatric acute lymphoblastic leukemia (ALL) patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The most appropriate approach by the physician is to provide a clear and honest discussion of treatment risk (option B). When discussing treatment for acute lymphoblastic leukemia with the father of a 4-year-old patient, the physician should openly communicate both the benefits and potential adverse effects of the treatment, as recommended by the NCCN Clinical Practice Guidelines in Oncology 1. This approach respects the family's autonomy and right to informed consent, allowing them to make decisions based on complete information. While the discussion should be tailored to the family's level of understanding, withholding information (options A and C) or making assumptions about what the family can comprehend (option D) would be paternalistic and unethical. Transparent communication builds trust between the healthcare team and the family, which is essential for the long-term management of a serious condition like leukemia. The physician should use clear language, check for understanding, and provide opportunities for questions throughout the discussion, as supported by the guidelines for pediatric ALL management 1.

Some key points to consider when discussing treatment risks with the family include:

  • The importance of risk-adapted therapy in improving survival rates for pediatric patients with ALL 1
  • The potential benefits and risks of hematopoietic stem cell transplantation and pharmacogenomics in the treatment of ALL 1
  • The need for ongoing supportive care and management to improve outcomes for patients with ALL 1
  • The unique considerations for AYA patients, who may receive treatment based on either a pediatric or an adult protocol, depending on local referral patterns and institutional practices 1

By providing a clear and honest discussion of treatment risks, the physician can empower the family to make informed decisions about their child's care and improve their overall quality of life.

From the Research

Approach to Discussing Treatment Risks

When discussing treatment risks with the family of a 4-year-old patient diagnosed with acute lymphoblastic leukemia, the physician should consider the following:

  • Provide a clear and honest discussion of treatment risks, as this approach is most appropriate for informed decision-making 2, 3, 4.
  • The treatment of acute lymphoblastic leukemia involves various risks and complications, including late treatment sequelae, second cancer, and other complications such as endocrinopathy, bone demineralization, obesity, and avascular necrosis of bone 2.
  • The patient's family should be informed about the potential benefits and risks of different treatment options, including chemotherapy, stem cell transplantation, and other therapies 5, 3, 4.
  • It is essential to discuss the individualized treatment plan, taking into account the patient's age, white blood cell count, and response to chemotherapy, as well as the potential for relapse and refractory disease 3, 4.

Key Considerations

  • The physician should avoid minimizing information that might be stressful for the family, as this could lead to inadequate understanding of the treatment risks and benefits 2, 3, 4.
  • Providing information only on the benefits of treatment or sharing only the information the physician thinks the family will understand is not an appropriate approach, as it may not give a comprehensive picture of the treatment risks and benefits 2, 3, 4.
  • A clear and honest discussion of treatment risks is crucial for the family to make informed decisions about their child's care.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Acute lymphoblastic leukemia.

Hematology. American Society of Hematology. Education Program, 2002

Research

Recent Advances in Managing Acute Lymphoblastic Leukemia.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2020

Related Questions

What are the hemoglobin targets for initiating chemotherapy in a patient with Acute Lymphoblastic Leukemia (ALL)?
What is the treatment for Acute Lymphoblastic Leukemia (ALL) blast crisis?
Is acute lymphocytic leukemia (ALL) a recognized medical condition?
Does Acute Lymphocytic Leukemia (ALL) exist?
What is the treatment approach for Acute Lymphoblastic Leukemia (ALL) with a positive Quantiferon (Interferon-Gamma Release Assay) test?
What is the management of generalized edema (anasarca)?
What is the most accurate assessment of the developmental status of an 18-month-old boy who can sit, walk, run, and climb with assistance, has a 20-word vocabulary, and is at the 50th percentile for length and weight?
What is the management plan for a patient with Type 2 Diabetes Mellitus (T2DM) and neuropathy, on long-term insulin therapy, with improving glycemic control, and taking Acarbose (100 mg orally three times a day), Jardiance (Empagliflozin, 10 mg orally daily), Metformin (500 mg orally twice daily), Pioglitazone (30 mg orally daily), Semaglutide (0.25 mg subcutaneously weekly), Insulin Lispro (14 units subcutaneously with lunch and dinner), and Insulin Glargine (40 units subcutaneously nightly), with normal Microalbuminuria (MAU) and no retinopathy, and also taking Gabapentin (100 mg orally three times a day) and Ramipril (10 mg orally daily)?
What is the reduction in Hemoglobin A1c (HbA1c) with metformin (biguanide) therapy?
What is the Insall-Salvati (I-S) index?
What are the diagnostic criteria for hypertension (high blood pressure)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.